Search | Clinical Trials Finder

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions: Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo; Biological · Drug
Lead sponsor: Serum Life Science Europe GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: gp145 C.6980 Vaccine, Placebo, Aluminum Hydroxide Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: CH505 TF chTrimer, 3M-05-AF, Aluminum hydroxide suspension; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: Purified Inactivated Zika Virus Vaccine (PIZV), Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Oakland Park, Florida • Meridian, Idaho • Wichita, Kansas + 2 more

Conditions: Dengue Fever
Interventions: DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel), Placebo for DEN1-80E; Biological
Lead sponsor: Hawaii Biotech, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mucositis, Neoplasms
Interventions: Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse; Drug
Lead sponsor: Oral Defense, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Hepatitis E, Immunisation
Interventions: HEV 239, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Norovirus, Healthy Participants
Interventions: NoV GI.1/GII.4 Bivalent VLP Vaccine; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chikungunya Virus
Interventions: CHIKV VLP/adjuvant, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 65 Years and older
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Miami, Florida • Miami Lakes, Florida • St. Petersburg, Florida + 7 more

Conditions: Botulism
Interventions: rBV A/B; Biological
Lead sponsor: California Department of Public Health; Other
Eligibility: 18 Years to 69 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Richmond, California • West Jefferson, Ohio

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 60 Years
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 7
States / cities: Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more

Conditions: Zika Virus, Zika Virus Infection
Interventions: VLA1601, Placebo; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Type 1 Diabetes Mellitus
Interventions: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo; Biological · Dietary Supplement
Lead sponsor: Diamyd Medical AB; Industry
Eligibility: 12 Years to 28 Years
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Newport Beach, California • Palo Alto, California • San Diego, California + 10 more

Conditions: Healthy Volunteer, HV
Interventions: AMA1-C1/Alhydrogel + CpG 7909; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland • Rochester, New York

Conditions: Norovirus
Interventions: Norovirus GI.1/GII.4 Bivalent VLP Vaccine, 0.9% sodium chloride (saline); Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 7 more

Conditions: Alzheimer's Disease
Interventions: CAD106, Placebo, Alum, MF59; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Up to 85 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more

Conditions: HIV Infections
Interventions: Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1996
U.S. locations: 3
States / cities: St Louis, Missouri • Rochester, New York • Seattle, Washington

Conditions: Plasmodium Falciparum Malaria
Interventions: Malaria ICC-1132, Alhydrogel; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Febuxostat XR, Maalox Advance Regular Strength liquid; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: HIV p17/p24:Ty-VLP, Aluminum hydroxide; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1996
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Malaria
Interventions: Pfs25-EPA/Alhydrogel; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy; Biological · Drug · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vulvovaginal Candidiasis
Interventions: NDV-3A, NDV-3, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Search by objective public record fields.

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Study of HBV-001 D1 in Healthy Adults

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis

Safety Study of Hepatitis E Vaccine (HEV239)

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults